Crucell had 2010 loss on vaccine write-downs

Crucell NV, the Dutch developer of therapeutic and prophylactic vaccines that Johnson & Johnson is seeking to acquire, has reported a 2010 operating loss on write-downs relating to a manufacturing problem.